Novo's trial of weight-loss drug shows improvement in fatty liver disease
Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty ...
Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs
A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...
Business Insider9d
Novo Nordisk Completes DKK 2.4 Billion Share Buyback
Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, buying back B shares worth DKK 2.4 billion. This initiative is part of a larger plan to repurchase ...